5 Hepatology Headlines You Missed in January 2026
Catch up on hepatic FDA news, expert insights on PBC and MASH developments, & more.
January 2026 opened with major momentum across hepatology, particularly in metabolic and viral liver disease. The US Food and Drug Administration (FDA)’s decision to grant Breakthrough Therapy Designation to pemvidutide marked a significant milestone for metabolic dysfunction-associated steatohepatitis (MASH), reflecting growing confidence in dual agonist strategies supported by robust histologic and noninvasive data. In parallel, long-awaited phase 3 results for bepirovirsen signaled meaningful progress toward functional cure in chronic hepatitis B, with consistent efficacy across a broad, global patient population and especially strong responses in patients with lower baseline HBsAg levels.